EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

被引：0
|
作者：
Dinh, M. [1 ]
Pithavala, Y. [1 ]
Chen, J. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-053
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Shaw, Alice T.
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd M.
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Clancy, Jill S.
    Li, Sherry
    Thurm, Holger
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Solomon, Benjamin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
    Bauer, Todd M.
    Martini, Jean-Francois
    Besse, Benjamin
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Toffalorio, Francesca
    Abbattista, Antonello
    Thurm, Holger
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Shaw, Alice T.
    Solomon, Benjamin J.
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).
    Shaw, Alice Tsang
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd Michael
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Abbattista, Antonello
    Toffalorio, Francesca
    Thurm, Holger C.
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven Chuan-Hao
    Chiari, Rita
    Gadgeel, Shirish M.
    Felip, Enriqueta
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [5] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [6] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [7] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [8] Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
    Qian, Jialin
    Chu, Tianqing
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2025, 17
  • [9] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [10] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
12345